QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

EWTX

QT55Edgewise Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
36.81
+1.99+5.72%
OverviewShort InterestFilings
EWTXQT55Edgewise Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
36.81+5.72%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand107.59M
Perf Week8.49%
Market Cap3.75BForward P/E-EPS next Y-1.77Insider Trans0.17%Shs Float-Perf Month17.12%
Enterprise Value3.72BPEG3.12EPS next Q-0.50Inst Own-Short Float-Perf Quarter22.50%
Income-176829526.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y61.66%
Sales-P/B7.56EPS next Y9.09%ROA-33.94%Short Interest-Perf YTD48.31%
Book/sh4.58P/C-EPS next 5Y-ROE-32.55%52W High40.77 -9.71%Perf Year154.04%
Cash/sh4.65P/FCF-EPS past 3/5Y-ROIC-40.15%52W Low12.15 202.96%Perf 3Y-
Dividend Est.-EV/EBITDA-21.12Sales past 3/5Y-Gross Margin0.00%Volatility6.27% 5.95%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-14.48%Oper. Margin0.00%ATR (14)2.39Perf 10Y-
Dividend Ex-Date-Quick Ratio22.61Sales Y/Y TTM-Profit Margin0.00%RSI (14)57.62Recom2.30
Dividend Gr. 3/5Y-Current Ratio22.61EPS Q/Q-6.98%SMA205.49%Beta1.25Target Price47.56
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA508.89%Rel Volume1.36Prev Close34.82
Employees117LT Debt/Eq0.01EarningsAug 06SMA20041.63%Avg Volume1.46MPrice36.81
IPO DateMar 26, 2021Option/ShortYes / YesEPS/Sales Surpr.8.00% -Net Debt/EBITDA0.17Volume1,990,150Change5.72%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-17-26ReiteratedRBC CapitalOutperform$48 → $59
Jun-17-26ReiteratedGoldman SachsNeutral$20 → $32
Jun-16-26ReiteratedLeerink Partners$50 → $52
Jun-02-26ReiteratedH.C. Wainwright$42 → $45
Jun-02-26ReiteratedRBC CapitalOutperform$42 → $48
Jun-01-26ReiteratedRaymond James$52 → $66
May-06-26ReiteratedTruist Financial$46 → $52
Mar-10-26ReiteratedRaymond James$46
Feb-26-26ReiteratedEvercore ISI$45
Feb-26-26ReiteratedStifel Nicolaus$25
Latest News
Jun-18-26
Jun-18-2610:31AM
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga
Jun-17-26
Jun-17-2611:02AM
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59Benzinga
09:05AM
Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga
08:20AM
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32Benzinga
06:22AM
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy TranscriptSeekingAlpha
03:43AM
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - SlideshowSeekingAlpha
Jun-16-26
Jun-16-2601:40PM
Edgewise Therapeutics Reports Improvements In Heart Drug TrialBenzinga
11:57AM
HC Wainwright & Co. Reiterates Buy on Edgewise Therapeutics, Maintains $45 Price TargetBenzinga
08:05AM
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga
07:05AM
Edgewise Therapeutics Says Topline Data From 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 In Obstructive And Nonobstructive Hypertrophic Cardiomyopathy Show No Relationship Observed Between Multiple Measures Of Systolic Function And Concentration Of EDG-7500Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A200
Gross Profit-200
Selling, General and Administrative Excl. Other403223
Research and Development15112791
Other Operating Expense-200
Operating Income-191-159-114
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-24-25-14
Net Income Before Taxes-168-134-100
Income Taxes
000
Consolidated Net Income-168-134-100
Net Income From Continuing Operations-168-134-100
Net Income-168-134-100
EPS (Recurring)-1.63-1.45-1.57
EPS (Basic, Before Extraordinaries)-1.63-1.45-1.57
EPS (Diluted)-1.63-1.45-1.57
EBITDA-166-132-98
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding1039264
Market Capitalization2,556——
Operating Lease Expense
———
Insider Trading Volume
$38.90$35.24$31.57$27.90$24.24● Close Price0.00M0.85M1.70M2.55M3.40MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Donovan Joanne M.CMOMay 05 '26Option Exercise7.08100,000708,00075,000May 05 12:00 AM
Donovan Joanne M.CMOMay 05 '26Sale38.5750,0001,928,4004,367May 05 12:00 AM
Donovan Joanne M.CMOMay 04 '26Sale31.295,230163,6634,367May 05 12:00 AM
Donovan Joanne M.CMOApr 01 '26Option Exercise7.0857,324405,854125,000Apr 02 12:00 AM
Donovan Joanne M.CMOApr 01 '26Sale32.3128,662926,0959,597Apr 02 12:00 AM
Donovan Joanne M.CMOMar 31 '26Option Exercise7.0842,676302,146153,662Mar 31 12:00 AM
Donovan Joanne M.CMOMar 31 '26Sale32.1221,338685,3089,597Mar 31 12:00 AM
Donovan Joanne M.CMOMar 27 '26Sale30.9816,358506,7349,597Mar 30 12:00 AM
Edris BadreddinDirectorJan 21 '26Option Exercise1.45220,479320,336135,291Jan 23 12:00 AM
Edris BadreddinDirectorJan 21 '26Sale29.44115,4713,399,46719,820Jan 23 12:00 AM
Russell Alan JChief Scientific OfficerNov 12 '25Option Exercise0.18200,00036,0001,147,365Nov 13 12:00 AM
Russell Alan JChief Scientific OfficerNov 12 '25Sale21.12100,0002,112,45023,400Nov 13 12:00 AM
Fox Jonathan CDirectorNov 11 '25Buy18.6410,700199,40323,702Nov 13 12:00 AM
Russell Alan JChief Scientific OfficerAug 26 '25Option Exercise0.18200,00036,0001,247,365Aug 28 12:00 AM
Russell Alan JChief Scientific OfficerAug 26 '25Sale14.60100,0001,459,76023,400Aug 28 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR